This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The invention herein discloses a pharmaceutical combination for use in the treatment of cancer comprising a DNA ligase IV inhibitor and a PARP inhibitor in synergistically effective amounts for simultaneous, separate or sequential administration to a subject in need thereof.

The invention herein discloses a pharmaceutical combination for use in the treatment of cancer comprising a DNA ligase IV inhibitor and a PARP inhibitor in synergistically effective amounts for simultaneous, separate or sequential administration to a subject in need thereof.

The present invention is concerned with deuterium-enriched substituted phenoxy-(3, 4-methylenedioxy)phenylacetic acid and acylsulfonamide derivatives of general structural formula I, their optically active or pure enantiomers and diastereomers, and pharmaceutical salts thereof,

##STR00001##

These compounds have selective antagonist activity for endothelin receptors or both endothelin and angiotensin II receptors, and are useful in the treatment of diseases mediated by endothelin and angiotensin-II and their receptors.

The present invention is concerned with deuterium-enriched substituted phenoxy-(3, 4-methylenedioxy)phenylacetic acid and acylsulfonamide derivatives of general structural formula I, their optically active or pure enantiomers and diastereomers, and pharmaceutical salts thereof,

##STR00001##

These compounds have selective antagonist activity for endothelin receptors or both endothelin and angiotensin II receptors, and are useful in the treatment of diseases mediated by endothelin and angiotensin-II and their receptors.

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

This invention relates to compounds of Formula (I):

##STR00001##

and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

This invention relates to compounds of Formula (I):

##STR00001##

and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

The present invention relates to a compound for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof. The present invention further relates to a composition for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof.